Toggle Main Menu Toggle Search

Open Access padlockePrints

Patterns of steroid use in patients with established rheumatoid arthritis commencing treatment with biologic or targeted synthetic DMARDs

Lookup NU author(s): Professor John IsaacsORCiD

Downloads


Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


Abstract

© The Author(s) 2025. Published by Oxford University Press on behalf of the British Society for Rheumatology. Objectives: To investigate the clinical use of steroids in established RA. Methods: A cohort of RA patients commencing treatment with biologic or targeted synthetic (b/ts) DMARDs was followed prospectively, with clinical data recorded pre-baseline and at the 3, 6 and 12-month follow-up. Patients were included in this analysis if they had completed the first year of follow-up and had data on steroid use available for at least one follow-up. The proportions of patients receiving steroids at different timepoints were compared and further differentiated between continued (receiving steroids at two consecutive timepoints) and newly started treatment. Lastly, mixed linear effect models were used to assess the relationship between clinical factors and steroid use. Results: The cohort (N=1846) had a median disease duration of 7years and, across each timepoint, ≈30% of patients received steroids, up to two-thirds of which continued treatment from a preceding follow-up. At 12months, the proportion of patients continuing treatment decreased, but more patients started steroid treatment (P<0.001). Linear mixed effects modelling further showed that steroid use was more common in patients who had required pre-baseline steroids [odds ratio (OR) 1.44 (95% CI 1.38, 1.49)] and in those on later-stage treatments [OR 1.15 (95% CI 1.08, 1.23)]. Conclusion: Despite the introduction of b/tsDMARDs, steroid use in this cohort continued over the first year of follow-up, particularly in patients with more severe RA. Together with previous data, this further highlights the need for future research and trials to better understand the right course of steroid administration to maximize efficacy and limit adverse side effects.


Publication metadata

Author(s): Stadler M, Bindra S, Cheung A, Yap CF, Bluett J, Plant D, Nair N, Hyrich K, Morgan A, Wilson AG, Isaacs JD, Barton A

Publication type: Article

Publication status: Published

Journal: Rheumatology Advances in Practice

Year: 2026

Volume: 10

Issue: 1

Online publication date: 22/12/2025

Acceptance date: 25/10/2025

Date deposited: 12/01/2026

ISSN (electronic): 2514-1775

Publisher: Oxford University Press

URL: https://doi.org/10.1093/rap/rkaf130

DOI: 10.1093/rap/rkaf130

Data Access Statement: The data underlying this article cannot be shared publicly for the privacy of individuals who participated in the study. The data will be shared upon reasonable request to the corresponding author.


Altmetrics

Altmetrics provided by Altmetric


Funding

Funder referenceFunder name
Manchester National Institute for Health and Care Research Biomedical Research Centre (grant 203308)
Versus Arthritis (grant 21754)

Share